Abstract
Upfront Imatinib with Selective Early Switching to Nilotinib Leads to Excellent Achievement of Deep Molecular Response in Chronic Phase CML: 5 Year (Final) Analysis of the TIDEL-II Study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have